ROLE OF GABAPENTINOIDS AMONG PATIENTS WITH CHRONIC PRURITUS

Efficacy and safety of pregabalin vs gabapentin among patients of chronic pruritus: A randomized study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046189

Enrollment

Registered

2022-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L299- Pruritus, unspecified

Interventions

Intervention1: PREGABALIN AMONG PATIENTS OF CHRONIC PRURITUS: Pregabalin 75mg twice a day orally is given to one group for 6 weeks for chronic pruritus patients Control Intervention1: Gabapentin among

Eligibility

Inclusion criteria

Inclusion criteria: Persistent pruritus for 6 weeks & above

Exclusion criteria

Exclusion criteria: 1. Patients with AST and ALT three times above the normal level 2. Creatinine clearance (Crcl) 3. Patients with pruritus of known dermatological causes such as Psoriasis, Lichen planus, Scabies, etc 4. Pregnant and lactating women 5. Patients taking opioids for therapeutic purpose

Design outcomes

Primary

Measure	Time frame
VISUAL ANALOGUE SCALETimepoint: BASELINE, 2ND WEEK AND 6TH WEEK	—

Secondary

Measure	Time frame
5D Pruritus Scale and Dermatology Life Quality IndexTimepoint: BASELINE, 2ND WEEK AND 6TH WEEK	—

Countries

India

Contacts

Public ContactDr Aswini S

AIIMS Jodhpur

drshobanpgimer@gmail.com8437726777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026